Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
NYS Entity Status
NYS Filing Date
JULY 24, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2013 - AORE 2ND AVE. DEVELOPMENT LLC
Around the Web
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- Ex-NY Senate leader Skelos gets new trial in corruption case
By JENNIFER PELTZ, Associated Press - Tuesday Sep 26, 2017
NEW YORK (AP) — Former New York state Senate leader Dean Skelos and his son were granted new trials Tuesday in their corruption case, with a federal appeals court citing a Supreme Court ruling that has already unraveled convictions of other powerful politicians.The court found the jury in Dean and Adam Skelos' case was wrongly instructed, in light of a recent Supreme Court ruling narrowing the definition of what it takes to convict a public official."Because we cannot conclude that the (instruction) error was harmless beyond a reasonable doubt, we are obliged to vacate the convictions," the 2nd Circuit Court of Appeals wrote.
- New Development: Soft in the Middle, Splashy Up Top
By STEFANOS CHEN - Friday Sep 15, 2017
The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]